Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders.

The field of AAV-gene therapy has experienced enormous advancements in the last decade. However, there is still ample space for improvement aimed at overcoming existing challenges that are slowing down the progressive trajectory of this field.